Cargando…

Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Fengzhi, Aljahdali, Ieman, Ling, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704566/ https://www.ncbi.nlm.nih.gov/pubmed/31439015 http://dx.doi.org/10.1186/s13046-019-1362-1

Ejemplares similares

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
por: Li, Fengzhi, et al.
Publicado: (2021)

Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases
por: Li, Fengzhi, et al.
Publicado: (2022)

FL118, acting as a ‘molecular glue degrader’, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy
por: Ling, Xiang, et al.
Publicado: (2022)

Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
por: Santha, Sreevidya, et al.
Publicado: (2020)

BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis
por: Filipchiuk, Carolina, et al.
Publicado: (2020)

Polymorphisms in Survivin (BIRC5 Gene) Are Associated with Age of Onset in Breast Cancer Patients
por: Sušac, Ilona, et al.
Publicado: (2019)

Survivin (BIRC5) regulates bladder fibrosis in a rat model of partial bladder outlet obstruction
por: Di, Xingpeng, et al.
Publicado: (2023)

What can Pakistan do to address maternal and child health over the next decade?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2015)

Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells
por: Conde, Marina, et al.
Publicado: (2017)

Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma
por: Troiano, Giuseppe, et al.
Publicado: (2018)

Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients
por: Rahban, Dariush, et al.
Publicado: (2019)

Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts
por: Oparina, Nina, et al.
Publicado: (2021)

A decade plus of translation: what do we understand?
por: Wang, Xiangdong, et al.
Publicado: (2012)

Changes in health and functioning of care home residents over two decades: what can we learn from population-based studies?
por: Barker, Robert O, et al.
Publicado: (2020)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

Mental health among clinicians: what do we know and what can we do?
por: Patel, Mittal, et al.
Publicado: (2021)

Two decades with omalizumab: what we still have to learn
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

What can we do about osteoarthritis?
por: Lohmander, L Stefan
Publicado: (2000)

Late presenters: what can we do?
por: Mussini, C
Publicado: (2012)

BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
por: Frazzi, Raffaele
Publicado: (2021)

Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
por: Abdulameer, Shaymaa Abdalwahed, et al.
Publicado: (2012)

Q&A: What do we know about influenza and what can we do about it?
por: Doherty, Peter C, et al.
Publicado: (2009)

Experimental Errors in QSAR Modeling Sets: What We Can Do and What We Cannot Do
por: Zhao, Linlin, et al.
Publicado: (2017)

Treatment of Laryngoceles: What Is the Progress over the Last Two Decades?
por: Zelenik, Karol, et al.
Publicado: (2014)

Cosmic debris: what it is and what we can do about it
por: Powell, Jonathan
Publicado: (2017)

Recalls of Cardiac Implants in the Last Decade: What Lessons Can We Learn?
por: Zhang, Shixuan, et al.
Publicado: (2015)

The gut microbiota in osteoarthritis: where do we stand and what can we do?
por: Hao, Xiaoxia, et al.
Publicado: (2021)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

Management of Achilles and patellar tendinopathy: what we know, what we can do
por: Aicale, Rocco, et al.
Publicado: (2020)

Hepatitis of unknown etiology in children: What we know and what we can do?
por: Zhu, Mingyu, et al.
Publicado: (2022)

Geriatric Radiation Oncology: What We Know and What Can We Do Better?
por: Roeder, Falk, et al.
Publicado: (2023)

Q&A: Antibiotic resistance: what more do we know and what more can we do?
por: Wright, Gerard D
Publicado: (2013)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

Subclinical atherosclerosis: what it is, what it means and what we can do about it
por: Toth, P P
Publicado: (2008)

Improve postoperative sleep: what can we do?
por: Su, Xian, et al.
Publicado: (2018)

Disability and Happiness in Iran: What Can We Do?
por: SOLTANI, Shahin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9qf60uo9cd1hhiptifiqll4qv6